PEPTIDE Registry

Reported experiences and published evidence, kept separate. Explore what people seek, what sources actually study and what remains unknown.

Collection closed. No participant results published.

What would you like to explore?

All groups and topics

Reported-use topics, not evidence grades or diagnoses. The catalog does not cover every possible experience.

Melanotan II

Editorial context from existing sources; independent scientific review pending. Numerical findings held. A reported-use topic does not establish direct evidence for that aim.

An afamelanotide product has a narrow approved context. TGA testing of a small set of melanotan sprays found content inconsistent with labels.

Do not transfer afamelanotide approval to melanotan II or interpret increased pigmentation as sunscreen protection. A targeted testing sample is not a market-wide prevalence estimate.

Sources and proposed-mechanism explanation

Pigmentation signaling is not equivalent to protection from ultraviolet injury. Afamelanotide and melanotan II must remain distinct.

Practice & Evidence: claims and limits

Collection, review and methods

8 documents · 24 educational profiles · 10 guides. Hosting authorization and reviews remain pending. Drafts are not reports; they do not establish effectiveness or safety.

Methods, consent and privacy

Understanding community practices What each evidence label means Stacks, mixtures and claims of synergy How we handle reported doses and cycles Reading a peptide quality report When someone says it worked Source errors, corrections and retractions From experience to a research question The proposed Community Observation Program Reading future observational results